

[Regional strategy to improve access to medicines and vaccines in the Eastern Mediterranean, 2020–2030, including lessons from the COVID-19 pandemic](#)

[WHO Global Benchmarking Tool \(GBT\) for evaluation of national regulatory system of medical products: revision VI](#)

[Manual for benchmarking of the national regulatory system of medical products and formulation of institutional development plans](#)

[Implementation guide for health systems recovery in emergencies: transforming challenges into opportunities](#)

[Delivering quality-assured medical products for all 2019–2023: WHO's five-year plan to help build effective and efficient regulatory systems](#)

[Implementing quality management systems in national regulatory authorities: examples and practices](#)

[Evaluating and publicly designating regulatory authorities as WHO listed authorities: policy document](#)

[Regulation of vaccines: building on existing drug regulatory authorities](#)

[Guidelines on regulatory preparedness for provision of marketing authorization of human pandemic influenza vaccines in non-vaccine-producing countries: annex 7, WHO Technical Report Series No. 1004](#)

[Managing conflicts of interest: a how-to guide for public pharmaceutical-sector committees in low- and middle-income countries \[LD1\]](#)

[Shaping the global innovation and access landscape for better paediatric medicines: Global Accelerator for Paediatric Formulations 2022–2024 strategy](#)

[Promoting access to medical technologies and innovation: intersections between public health, intellectual property and trade](#)

[Guidance for post-market surveillance and market surveillance of medical devices, including in vitro diagnostics](#)

[Policy paper on traceability of medical products](#)

[The WHO Member State Mechanism on Substandard and Falsified Medical Products: how WHO Member States work together to safeguard access to safe and effective medicines, vaccines and other medical products](#)

[A study on the public health and socioeconomic impact of substandard and falsified medical products](#)

[WHO model list of essential medicines: 22nd list \(2021\)](#)

[WHO model list of essential medicines for children: 8th list \(2021\)](#)

[The interagency emergency health kit 2017: medicines and medical devices for 10 000 people for approximately three months](#)

[The pursuit of responsible use of medicines: sharing and learning from country experiences](#)

[The role of intellectual property in local production in developing countries: opportunities and challenges](#)

[Regulation of medical devices: a step-by-step guide](#)

Blood and other products of human origin

[Action framework to advance universal access to safe, effective and quality-assured blood products 2020–2023 \[LD3\]](#)

[Global status report on blood safety and availability 2021](#)

[Global status report on blood safety and availability 2016](#)

[Guidance on centralization of blood donation testing and processing](#)

[Guidance on increasing supplies of plasma-derived medicinal products in low- and middle-income countries through fractionation of domestic plasma](#)

[A guide to establishing a national haemovigilance system](#)

[Maintaining a safe and adequate blood supply and collecting convalescent blood plasma in the context of the COVID-19 pandemic: interim guidance](#)

[Regional status report on blood safety and availability 2016](#)

[Strategic framework for blood safety and availability 2016–2025](#)

[The urgent need to implement patient blood management: policy brief](#)

Sunday 12th of May 2024 04:53:39 PM